Navigation Links
GenVec Achieves Second Milestone in Collaboration
Date:12/6/2011

GAITHERSBURG, Md., Dec. 6, 2011 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) today announced that it has achieved the second milestone in its collaboration with Novartis (NYSE: NVS), related to the development of treatments for hearing loss and balance disorders. The milestone was triggered by the successful completion of certain preclinical development activities.

"Completing this milestone reflects sustained progress and we look forward to reaching additional milestones with Novartis in this very exciting program," said Dr. Paul Fischer, GenVec's President and Chief Executive Officer.

About the CollaborationIn January 2010, GenVec entered into a worldwide licensing and collaboration agreement with Novartis to discover and develop novel treatments for hearing loss and balance disorders. Under the terms of the agreement, if certain clinical, regulatory, and sales milestones are met, GenVec is eligible to receive up to $213.6 million, including upfront and milestone payments in addition to royalties on future sales.

In August 2010, we entered into an additional agreement with Novartis, to manufacture clinical trial material for up to two lead product candidates for this program.

About GenVecGenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss a
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Expands Contract Supporting Malaria Vaccine Program
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. GenVec Announces Third Quarter 2009 Results Conference Call
7. GenVec Reports Third Quarter 2009 Financial Results
8. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
9. GenVec to Present at the 13th Annual BIO CEO & Investor Conference
10. GenVec To Host Fourth Quarter and Year-End 2010 Earnings Call and Webcast
11. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 The ... IACRN), a non-profit organization based in Pittsburgh, ... Excellence and Safety (ACRES), a Massachusetts non-profit ... strategic alliance agreement, setting the stage for multiple ... enhance clinical research quality and safety through specialized ...
(Date:9/29/2014)... DUBLIN , Sept. 29, 2014 ... "Oligonucleotide Synthesis Market by Product & Services, End-User ... to their offering. The global oligonucleotide ... 2019 from $1,070.7 million in 2014, growing at a ... oligonucleotide synthesis market is categorized on the basis of ...
(Date:9/29/2014)... , September 29, 2014 ... report "Epigenetics Market by Product (Modifying Enzymes, DNA ... Bisulphite Conversion Kit, Reagents), by Research Area ... Global Forecast to 2019", published by MarketsandMarkets, ... drivers, restraints, opportunities, current market trends, and ...
(Date:9/29/2014)... TORONTO , Sept. 29, 2014 /PRNewswire/ - SQI ... company that develops and commercializes proprietary technologies and products ... appointment of Peter Winkley to Chairman of ... Ricks .  Mr. Ricks will continue to serve as ... provide leadership to the Company.  "We ...
Breaking Biology Technology:IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3Epigenetics Market Worth $783.17 Million by 2019 2Epigenetics Market Worth $783.17 Million by 2019 3Epigenetics Market Worth $783.17 Million by 2019 4SQI Diagnostics Announces New Chairman of Board of Directors 2
... , SOUTH BURLINGTON, Vt ., June 22 As previously ... Property including the patents of the Del-ID system to an Ontario ... is now pleased to announce leadership changes and appointments to QTECH,s Management Team ... of Kitchener, Ontario . , ...
... ... , ... Forza Silicon Corporation announced today that it is in a joint development effort with a ... CMOS image sensors., , , , ,Forza Silicon Corporation Chief Technology Officer, Daniel Van Blerkom, ...
... Researchers at Rensselaer Polytechnic Institute have developed a simple ... nanomaterial graphene. The new technique works at room temperature, ... mass production of graphene. An atom-thick sheet ... unique mechanical and electrical properties and is considered a ...
Cached Biology Technology:delSECUR CORPORATION Announces Organizational Update as QTECH SYSTEMS INC. Expands Leadership Team 2delSECUR CORPORATION Announces Organizational Update as QTECH SYSTEMS INC. Expands Leadership Team 3Forza Silicon Announces High Dynamic Range CMOS Sensor Development 2Researchers at Rensselaer Polytechnic Institute develop new method for mass-producing graphene 2Researchers at Rensselaer Polytechnic Institute develop new method for mass-producing graphene 3
(Date:9/29/2014)... Illinois scientists have found compounds that boost liver detoxification ... pretty unlikely placethe crushed seeds left after oil extraction ... "The bioactive compounds in Camelina sativa seed, ... mixture of phytochemicals that work together synergistically far better ... promising nutritional supplement because its bioactive ingredients increase the ...
(Date:9/29/2014)... deemed inaccessible or esoteric. Yet in the modern world, ... daily lives and a decisive role in the discovery ... scenes. , UC Santa Barbara,s Paul Atzberger, a professor ... of mechanical engineering, often works in areas where science ... in the Proceedings of the National Academy of ...
(Date:9/29/2014)... age of dinosaurs, gigantic reptilesdistant relatives of modern crocodilesruled ... water and it was thought they didn,t much interact. ... Knoxville, researcher in the thigh of one of these ... Drumheller, an earth and planetary sciences lecturer, and her ... 220-million-year-old bite marks in the thigh bones of an ...
Breaking Biology News(10 mins):New way to detox? 'Gold of Pleasure' oilseed boosts liver detoxification enzymes 2At the interface of math and science 2At the interface of math and science 3At the interface of math and science 4Tooth serves as evidence of 220 million-year-old attack 2
... valves, can drive experimental samples through a lab-on-a-chip in ... This development could significantly simplify the process of conducting ... research will be published online in the Proceedings ... of July 20. A lab-on-a-chip, or microfluidic ...
... Mice with a defective mitochondrial protein called MCLK1 ... should spell disaster, yet according to a study in ... slower rate and live longer than normal mice. ... aging process; over time, reactive oxygen species produced by ...
... Malaria Research Institute have for the first time produced ... quantity to generate a significant immune response in mice ... vaccine. Antibodies induced by Pfs48/45 protein vaccine effectively blocked ... , as it grows within the mosquito. Sexual development ...
Cached Biology News:Music is the engine of new U-M lab-on-a-chip device 2Vaccine blocks malaria transmission in lab experiments 2
Bethyl Laboratories Ready-To-Use IHC Bluing Reagent is used following IHC hematoxylin counterstaining with immunohistochemical procedures. Shelf-Life: 1 year from date of receipt...
... 3F10B10. Immunogen: Synthetic peptide ... of JAB1 (Jun activation domain-binding ... Specific for the JAB1 protein. ... 293T Jurkat cell lysates). ...
ready-to-use solution...
...
Biology Products: